Akebia Announces Approval of Vafseo® (vadadustat) in Australia and Provides Commercial UpdatePRNewsWire • 09/26/23
Akebia Therapeutics Reports Second Quarter 2023 Financial Results and Recent Business HighlightsPRNewsWire • 08/25/23
Akebia Therapeutics to Report Second Quarter Financial Results and Discuss Recent Business HighlightsPRNewsWire • 08/23/23
Akebia Therapeutics to Report Second Quarter Financial Results by August 25, 2023PRNewsWire • 08/17/23
Akebia Therapeutics Completed Type A Meeting with the FDA and Expects to Resubmit Vadadustat NDA in Third Quarter 2023PRNewsWire • 07/18/23
Akebia Therapeutics Announces Positive Top-Line Results of Phase 4 IMPACT Study of Auryxia® (ferric citrate) for In-Center and Home Dialysis PatientsPRNewsWire • 06/29/23
Is Akebia Therapeutics (AKBA) Stock Outpacing Its Medical Peers This Year?Zacks Investment Research • 06/19/23
All You Need to Know About Akebia Therapeutics (AKBA) Rating Upgrade to BuyZacks Investment Research • 06/02/23
Akebia Therapeutics Enters into License Agreement with Medice Arzneimittel Pütter GmbH&Co.KG for the Commercialization of Vafseo® for the Treatment of Anemia associated with CKD in Europe and AustraliaPRNewsWire • 05/25/23